Immunogenicity and safety of an inactivated SARS‐CoV‐2 vaccine in people living with HIV: A cross‐sectional study
- 28 May 2022
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (9) , 4224-4233
Abstract
We aimed to analyze the efficacy and safety of an inactivated SARS‐CoV‐2 vaccine in people living with HIV (PLWH). A total of 143 PLWH and 50 healthy individuals were included in this study. A commercially available magnetic chemiluminescence enzyme immunoassay kit was used to detect serum IgG and IgM antibodies against SARS‐CoV‐2. Serum levels of SARS‐CoV‐2‐specific IgG were significantly higher in the control group than in the PLWH group (p = 0.001). Overall, 76% of individuals in the control group were detected with seropositivity IgG against SARS‐CoV‐2 compared to 58% in the PLWH group (p = 0.024). In PLWH with IgG seropositivity, CD4+ T‐cell counts before antiretroviral therapy (ART) was higher (p = 0.015). Multivariable analysis indicated that CD4+ T cells at IgG detection (odds ratio [OR] = 1.004, p = 0.006) and time after vaccination (OR = 0.977, p = 0.014) were independently associated with seropositivity IgG against SARS‐CoV‐2 in PLWH. Neutralizing antibody (nAb) titers in PLWH against wild‐type SARS‐CoV‐2 were similar to those in the control group (p = 0.160). The proportion of seropositive nAbs against wild‐type SARS‐CoV‐2 was also similar (95% in the control group vs. 97% in the PLWH group, p = 0.665). Similar results were obtained when nAb was detected against the delta variants with similar titers (p = 0.355) and a similar proportion of seropositive nAbs were observed (p = 0.588). All the side effects observed in our study were mild and self‐limiting. The inactivated COVID‐19 vaccine appears to be safe with good immunogenicity in Chinese PLWH.Keywords
This publication has 34 references indexed in Scilit:
- Prospects for a vaccine to prevent HIV-related tuberculosisCurrent Opinion in HIV and AIDS, 2018
- Pulmonary disease in HIV-infected adults in the era of antiretroviral therapyAIDS, 2018
- HIV Infection and Risk of Cardiovascular Diseases Beyond Coronary Artery DiseaseCurrent Atherosclerosis Reports, 2017
- A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian AdultsMedicine, 2016
- Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised HostClinical Infectious Diseases, 2014
- HIV infection and cardiovascular diseaseEuropean Heart Journal, 2014
- Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected personsInternational Journal of STD & AIDS, 2013
- A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis –infected AdultsAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Immunization in the adult immunocompromised hostAutoimmunity Reviews, 2012
- Pneumococcal Vaccination of HIV-Infected Individuals: Safety and EfficacyAIDS Patient Care and STDs, 1997